An MS medication decision is one of the most difficult decisions for someone with MS and their neurologist to make. After 39 years with MS, and with four disease-modifying therapies (DMTs) on my medical chart, I’m definitely on the hit-it-fast, hit-it-hard side of that treatment decision.
So, I was pleased to read an article in Brain & Life magazine reporting that “doctors today are less likely to wait to start (DMT) treatment. Research shows that treating MS with an immune-suppressant therapy beginning with the first attack not only may prevent future flare-ups but also may slow disease progression.”
The article outlines the arguments for early treatment, but it also provides examples of cases where neurologists have taken a wait-and-see approach. And it follows several people through their MS medication decision process. It’s one of the best articles I’ve read on this subject, providing a good overview of all 17 DMTs that have been approved by the Food and Drug Administration. It weighs the benefits and risks of each and also compares slow and fast treatment approaches.
Old school or new school?
Some in the neurology community consider the different approaches to be old school versus new school. One of the new schoolers is Dr. Aaron Boster, a neurologist who specializes in MS in Columbus, Ohio. Though I’ve never been his patient, everything that I’ve read or viewed tells me that Dr. Boster is a neurologist who gets it. He’s firmly in the treat-it-fast camp, but he also understands that any treatment decision must involve a patient’s overall lifestyle. Dr. Boster is not alone in his views, but he certainly has a unique way of getting his views out to the MS community:
As you can see, there’s a lot to consider when you’re deciding the best way to treat your MS. To help you out a bit, here’s a list of disease-modifying therapies that are approved for use in the United States. (Most are also approved elsewhere in the world). It might be useful to take it with you the next time you talk to your neurologist.
MS Medications
| DMT | EFFICACY** | TYPE |
| Ocrevus (ocrelizumab) | High | Infusion |
| Lemtrada (alemtuzumab) | High | Infusion |
| Tysabri (natalizumab) | High | Infusion |
| Aubagio (teriflunomide) | Medium | Pill |
| Gilenya (fingolimod) | Medium | Pill |
| Tecfidera (dimethyl fumarate) | Medium | Pill |
| Mavenclad (cladribine) | Medium | Pill |
| Mayzent (siponimod) | Medium | Pill |
| Avonex (interferon beta-1a) | Low | Shot |
| Betaseron (interferon beta-1b) | Low | Shot |
| Copaxone (glatiramer acetate)* | Low | Shot |
| Extavia (interferon beta-1b) | Low | Shot |
| Glatopa (glatiramer acetate) | Low | Shot |
| Mylan (glatiramer acetate) | Low | Shot |
| Plegridy (interferon beta-1a) | Low | Shot |
| Rebif (interferon beta-1a) | Low | Shot |
| * Also available as a generic | ||
| **Efficacy ratings from clinical trials noted in Brain & Life |
(A version of this post first appeared as my column on the Multiple Sclerosis News Today website).
(Featured image by Gerd Altmann from Pixabay)
